Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Non Operating Investment Income (2023 - 2025)

Historic Non Operating Investment Income for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to $196000.0.

  • Mereo BioPharma's Non Operating Investment Income rose 43220.34% to $196000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $668000.0, marking a year-over-year increase of 18664.07%. This contributed to the annual value of -$419000.0 for FY2024, which is 27102.04% down from last year.
  • Latest data reveals that Mereo BioPharma reported Non Operating Investment Income of $196000.0 as of Q3 2025, which was up 43220.34% from -$101000.0 recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Non Operating Investment Income peaked at $542000.0 during Q1 2023, and registered a low of -$448000.0 during Q1 2024.
  • In the last 3 years, Mereo BioPharma's Non Operating Investment Income had a median value of -$64000.0 in 2024 and averaged $33700.0.
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first plummeted by 18265.68% in 2024, then skyrocketed by 43220.34% in 2025.
  • Mereo BioPharma's Non Operating Investment Income (Quarter) stood at -$195000.0 in 2023, then surged by 180.51% to $157000.0 in 2024, then increased by 24.84% to $196000.0 in 2025.
  • Its last three reported values are $196000.0 in Q3 2025, -$101000.0 for Q2 2025, and $416000.0 during Q1 2025.